Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials

Blood (2017) 130 (Supplement 1): 2016.

https://doi.org/10.1182/blood.V130.Suppl_1.2016.2016

Published: 2017

Journal Articles

Centrosomal Clustering – a Novel Therapeutic Target for Multiple Myeloma.

Marc S Raab, MD, Iris Breitkreutz, MD, Blanka Rebacz, PhD, Thomas O Larsen, PhD, Ludmila Wagner, MSc, Patrick Hayden, MD, MRCPath, Anthony D. Ho, MD, PhD, Mads H Clausen, PhD, Hartmut Goldschmidt, MD, Kenneth C. Anderson, MD, Alwin Kraemer, MD

Blood (2009) 114 (22): 300.

https://doi.org/10.1182/blood.V114.22.300.300

Published: 2009

Journal Articles

Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling

Marc S. Raab, Iris Breitkreutz, Giovanni Tonon, Jing Zhang, Patrick J. Hayden, Thu Nguyen, Johannes H. Fruehauf, Boris K. Lin, Dharminder Chauhan, Teru Hideshima, Nikhil C. Munshi, Kenneth C. Anderson, Klaus Podar

Blood (2009) 113 (7): 1513–1521.

https://doi.org/10.1182/blood-2008-05-157040

Published: 2009

Includes: Supplemental data

Journal Articles

The Novel, Orally Available Multi-Kinase Inhibitor BAY 73-4506 in Multiple Myeloma

Iris Breitkreutz, Marc S Raab, Olaf Christensen, Alexander Zimmerhackl, Jing Zhang, Simona Blotta, Teru Hideshima, Dharminder Chauhan, Scott Wilhelm, Kenneth C Anderson, MD, Klaus Podar, MD, MSc, PhD

Blood (2008) 112 (11): 2766.

https://doi.org/10.1182/blood.V112.11.2766.2766

Published: 2008

Journal Articles

GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Growth in Vivo .

Marc S Raab, Iris Breitkreutz, Blanca Rebacz, Thu Nguyen, Patrick J. Hayden, Mads H Clausen, Thomas O. Larsen, Johannes Fruehauf, Kenneth C. Anderson, Alwin Kraemer

Blood (2008) 112 (11): 1639.

https://doi.org/10.1182/blood.V112.11.1639.1639

Published: 2008

Journal Articles

Targeting PKC: A Novel Role for Beta-catenin in ER Stress and Apoptotic Signaling

Marc S Raab, Iris Breitkreutz, Giovanni Tonon, Jing Zhang, Johannes Fruehauf, Boris K Lin, Dharminder Chauhan, Teru Hideshima, Nikhil Munshi, Kenneth C. Anderson, Klaus Podar

Blood (2008) 112 (11): 2763.

https://doi.org/10.1182/blood.V112.11.2763.2763

Published: 2008

Journal Articles

Targeting Proteinkinase C Alters ER-Stress and b-Catenin Signaling in Multiple Myeloma: Therapeutic Implications.

Marc S. Raab, MD, Klaus Podar, MD, PhD, Jing Zhang, MSc, Giovanni Tonon, MD, Johannes H. Fruehauf, MD, Iris Breitkreutz, MD, Boris K. Lin, MD, PhD, Teru Hideshima, MD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 258.

https://doi.org/10.1182/blood.V110.11.258.258

Published: 2007

Journal Articles

Targeting CCR1 for the Treatment of Osteolytic Bone Disease in Multiple Myeloma.

Sonia Vallet, MD, Noopur Raje, MD, MariaTeresa Fulciniti, Kenji Ishitsuka, MD, Teru Hideshima, MD, Klaus Podar, MD, Samantha Pozzi, MD, Iris Breitkreutz, MD, Tanyel Kiziltepe, PhD, Yutaka Okawa, MD, Hiroshi Ikeda, MD, Loredana Santo, MD, Siddhartha Mukherjee, MD, Nileshwari Vaghela, Diana Cirstea, MD, Mario Boccadoro, MD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 2503.

https://doi.org/10.1182/blood.V110.11.2503.2503

Published: 2007

Journal Articles

Inhibition of Hsp90 Targets Multiple Myeloma Cell Growth, Angiogenesis, and Osteoclastogenesis in the BM Microenvironment.

Yutaka Okawa, Teru Hideshima, Hiroshi Ikeda, Sonia Vallet, Tanyel Kiziltepe, Noopur Raje, Hiroshi Yasui, Sotaro Enatsu, Samantha Pozzi, Iris Breitkreutz, Klaus Podar, Paul G. Richardson, Kenneth C. Anderson

Blood (2007) 110 (11): 2522.

https://doi.org/10.1182/blood.V110.11.2522.2522

Published: 2007

Journal Articles

The Novel, Orally Available Multi-Kinase Inhibitor BAY 73-4506 Targets Myeloma Cells and Their Bone Marrow Microenvironment.

Marc S. Raab, MD, Iris Breitkreutz, MD, Podar Klaus, MD, PhD, Jing Zhang, MSc, Simona Blotta, MD, Olaf Christensen, MD, Teru Hideshima, MD, Dharminder Chauhan, PhD, Scott Wilhelm, PhD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 2525.

https://doi.org/10.1182/blood.V110.11.2525.2525

Published: 2007

Journal Articles

Multiple Myeloma Cell-Osteoblast Interaction Results in Impaired Bone Formation.

Sonia Vallet, MD, Teru Hideshima, MD, Samantha Pozzi, MD, Nileshwari Vaghela, Gaurav Gharti-Chhetri, Siddhartha Mukherjee, MD, Iris Breitkreutz, MD, Tanyel Kiziltepe, PhD, Yutaka Okawa, MD, Hiroshi Ikeda, MD, Loredana Santo, MD, Diana Cirstea, MD, Mario Boccadoro, MD, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2007) 110 (11): 4764.

https://doi.org/10.1182/blood.V110.11.4764.4764

Published: 2007

Journal Articles

Lenalidomide and Bortezomib: Targeting Osteoclastogenesis, Osteoclast Survival Factors, and Bone Remodeling Markers in Multiple Myeloma.

Iris Breitkreutz, MD, Marc S. Raab, MD, Sonia Vallet, MD, Teru Hideshima, MD, Noopur Raje, MD, Constantine Mitsiades, MD, PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 1184.

https://doi.org/10.1182/blood.V110.11.1184.1184

Published: 2007

Journal Articles

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts

Blood (2007) 110 (10): 3744–3752.

https://doi.org/10.1182/blood-2007-05-093294

Published: 2007

Includes: Supplemental data

Journal Articles

The BAFF Inhibitor AMG523 Blocks Adhesion and Survival of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment: Clinical Implication.

Yu-Tzu Tai, PhD, Jiangchun Xu, M.D., Xian-Feng Li, M.S., Iris Breitkreutz, M.D., Klaus Podar, M.D. Ph.D., Teru Hideshima, M.D. Ph.D., Robert Schlossman, M.D., Paul Richardson, M.D., Nikhil C. Munshi, M.D., Kenneth C. Anderson, M.D.

Blood (2006) 108 (11): 3452.

https://doi.org/10.1182/blood.V108.11.3452.3452

Published: 2006

Journal Articles

Inhibition of ERK1/2 Activity by the MEK1/2 Inhibitor AZD6244 (ARRY-142886) Induces Human Multiple Myeloma Cell Apoptosis in the Bone Marrow Microenvironment: A New Therapeutic Strategy for MM.

Yu-Tzu Tai, PhD, Xian-Feng Li, M.S., Iris Breitkreutz, M.D., Weihua Song, M.D., Peter Burger, B.S., Matthew Rumizen, Teru Hideshima, M.D. Ph.D., Klaus Podar, M.D. Ph.D., Irene Ghobrial, M.D., Robert Schlossman, M.D., Paul Richardson, M.D., Nikhil C. Munshi, M.D., Kenneth C. Anderson, M.D.

Blood (2006) 108 (11): 3460.

https://doi.org/10.1182/blood.V108.11.3460.3460

Published: 2006

Journal Articles

Targeting PKC in Multiple Myeloma: In Vitro and In Vivo Effects of the Novel, Orally Available Small-Molecule Inhibitor Enzastaurin (LY317615.HCl).

Marc S. Raab, MD, Klaus Podar, MD, PhD, Jing Zhang, MSc, Douglas McMillin, PhD, Iris Breitkreutz, MD, Yu-Tzu Tai, PhD, Boris Lin, MD, PhD, Irene Ghobrial, MD, Nikhil Munshi, MD, Teru Hideshima, MD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 3466.

https://doi.org/10.1182/blood.V108.11.3466.3466

Published: 2006

Journal Articles

AZD6244 (ARRY-142886), a Potent and Selective MEK1/2 Inhibitor Blocks the ERK1/2 Signaling Pathway, Inhibits Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications.

Iris Breitkreutz, MD, Sonia Vallet, MD, Marc S. Raab, MD, Xianfeng Li, Noopur Raje, MD, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Nikhil Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2006) 108 (11): 3467.

https://doi.org/10.1182/blood.V108.11.3467.3467

Published: 2006

Journal Articles

Lenalidomide and Bortezomib Inhibit Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications.

Iris Breitkreutz, MD, Sonia Vallet, MD, Marc S. Raab, MD, Yu-Tzu Tai, PhD, Noopur Raje, MD, Teru Hideshima, MD,PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, Paul Richardson, MD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 3485.

https://doi.org/10.1182/blood.V108.11.3485.3485

Published: 2006

Journal Articles

MLN3897, a Novel CCR1 Antagonist, Inhibits Osteoclastogenesis by Blocking Early ERK Activation.

Sonia Vallet, MD, Noopur Raje, MD, Kenji Ishitsuka, MD, Teru Hideshima, MD, Klaus Podar, MD, Petter Veiby, Iris Breitkreutz, MD, Tanyel Kizeltepe, PHD, Hiroshi Yasui, MD, Enrique M. Ocio, MD, Norihiko Shiraishi, Marco Ladetto, MD, Mario Boccadoro, MD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 1636.

https://doi.org/10.1182/blood.V108.11.1636.1636

Published: 2006

Journal Articles

Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)

Klaus Podar, Marc S. Raab, Jing Zhang, Douglas McMillin, Iris Breitkreutz, Yu-Tzu Tai, Boris K. Lin, Nikhil Munshi, Teru Hideshima, Dharminder Chauhan, Kenneth C. Anderson

Blood (2006) 109 (4): 1669–1677.

https://doi.org/10.1182/blood-2006-08-042747

Published: 2006

Includes: Supplemental data

NARROW

A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials

Centrosomal Clustering – a Novel Therapeutic Target for Multiple Myeloma.

Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling

The Novel, Orally Available Multi-Kinase Inhibitor BAY 73-4506 in Multiple Myeloma

GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Growth in Vivo .

Targeting PKC: A Novel Role for Beta-catenin in ER Stress and Apoptotic Signaling

Targeting Proteinkinase C Alters ER-Stress and b-Catenin Signaling in Multiple Myeloma: Therapeutic Implications.

Targeting CCR1 for the Treatment of Osteolytic Bone Disease in Multiple Myeloma.

Inhibition of Hsp90 Targets Multiple Myeloma Cell Growth, Angiogenesis, and Osteoclastogenesis in the BM Microenvironment.

The Novel, Orally Available Multi-Kinase Inhibitor BAY 73-4506 Targets Myeloma Cells and Their Bone Marrow Microenvironment.

Multiple Myeloma Cell-Osteoblast Interaction Results in Impaired Bone Formation.

Lenalidomide and Bortezomib: Targeting Osteoclastogenesis, Osteoclast Survival Factors, and Bone Remodeling Markers in Multiple Myeloma.

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts

The BAFF Inhibitor AMG523 Blocks Adhesion and Survival of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment: Clinical Implication.

Inhibition of ERK1/2 Activity by the MEK1/2 Inhibitor AZD6244 (ARRY-142886) Induces Human Multiple Myeloma Cell Apoptosis in the Bone Marrow Microenvironment: A New Therapeutic Strategy for MM.

Targeting PKC in Multiple Myeloma: In Vitro and In Vivo Effects of the Novel, Orally Available Small-Molecule Inhibitor Enzastaurin (LY317615.HCl).

AZD6244 (ARRY-142886), a Potent and Selective MEK1/2 Inhibitor Blocks the ERK1/2 Signaling Pathway, Inhibits Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications.

Lenalidomide and Bortezomib Inhibit Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications.

MLN3897, a Novel CCR1 Antagonist, Inhibits Osteoclastogenesis by Blocking Early ERK Activation.

Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only